Search

Your search keyword '"Nador, G"' showing total 9 results
Start Over Author "Nador, G" Database OAIster
9 results on '"Nador, G"'

1. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients

Author

Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, Montillo, M, Tedeschi A., Rossi D., Motta M., Quaresmini G., Rossi M., Coscia M., Anastasia A., Rossini F., Cortelezzi A., Nador G., Scarfo L., Cairoli R., Frustaci A. M., Dalceggio D., Picardi P., de Paoli L., Orlandi E., Rambaldi A., Massaia M., Gaidano G., Montillo M., Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, Montillo, M, Tedeschi A., Rossi D., Motta M., Quaresmini G., Rossi M., Coscia M., Anastasia A., Rossini F., Cortelezzi A., Nador G., Scarfo L., Cairoli R., Frustaci A. M., Dalceggio D., Picardi P., de Paoli L., Orlandi E., Rambaldi A., Massaia M., Gaidano G., and Montillo M.

Published
2015

2. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens

Author

Nosari, A, Cairoli, R, Ciapanna, D, Gargantini, L, Intropido, L, Baraté, C, Scarpati, B, Santoleri, L, Nador, G, Pezzetti, L, Morra, E, Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, Morra E., Nosari, A, Cairoli, R, Ciapanna, D, Gargantini, L, Intropido, L, Baraté, C, Scarpati, B, Santoleri, L, Nador, G, Pezzetti, L, Morra, E, Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, and Morra E.

Abstract

Systematic data on the ability of pegfilgrastim to mobilize stem cells after chemotherapy are scarce. We evaluated the efficacy of a single 6mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. Between July 2004 and October 2005, 17 aggressive non-Hodgkin's lymphoma and 11 poor-risk Hodgkin's lymphoma were treated with cycles containing cisplatin-aracytin. At the end of chemotherapy, the patients received 6mg of pegfilgrastim. Duration of grade 4 neutropenia, adverse events, time to neutrophil recovery, peak and harvest of CD34+ cells were recorded. Twenty-seven out of 28 patients harvested a median of 17.3 × 106/CD34+ cells (range 2.5-28.9) after a median of 9 days (range 8-12 days), with a single apheresis procedure in 25 cases. All patients had grade 3-4 neutropenia, median duration 3 days. The only adverse event was mild bone pain. To date, 13 patients have been autografted with a median of 15.4 × 106 CD34+ pegfilgrastim-mobilized cells per kg (range 2.5-28.9) with rapid and sustained engraftment. Mobilization, harvesting and autografting of pegfilgrastim-mobilized PBC can be successfully achieved in pretreated patients with aggressive lymphoma.

Published
2006

3. Development of Land Use Regression Models for PM(2.5), PM(2.5) Absorbance, PM(10) and PM(coarse) in 20 European Study Areas; Results of the ESCAPE Project.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., Hoek, G., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., and Hoek, G.

Published
2012

4. Development of Land Use Regression Models for PM(2.5), PM(2.5) Absorbance, PM(10) and PM(coarse) in 20 European Study Areas; Results of the ESCAPE Project.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., Hoek, G., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., and Hoek, G.

Published
2012

5. Development of Land Use Regression Models for PM(2.5), PM(2.5) Absorbance, PM(10) and PM(coarse) in 20 European Study Areas; Results of the ESCAPE Project.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., Hoek, G., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Eeftens, M.R., Beelen, R.M.J., de Hoogh, K., Bellander, T., Cesaroni, G., Cirach, M., Declercq, C., Dedele, A., Dons, E., de Nazelle, A., Dimakopoulou, K., Eriksen, K., Falq, G., Fischer, P., Galassi, C., Grazuleviciene, R., Heinrich, J., Hoffmann, B., Jerrett, M., Keidel, D., Korek, M., Lanki, T., Lindley, S., Madsen, C., Molter, A., Nador, G., Nieuwenhuijsen, M., Nonnemacher, M., Pedeli, X., Raaschou-Nielsen, O., Patelarou, E., Quass, U., Ranzi, A., Schindler, C., Stempfelet, M., Stephanou, E., Sugiri, D., Tsai, M.Y., Yli-Tuomi, T., Varro, M.J., Vienneau, D., von Klot, S., van der Wolf, K., Brunekreef, B., and Hoek, G.

Published
2012

7. IMPACT OF KIT MUTATIONS IN ACUTE MYELOID LEUKAEMIA WITH INV(16)

Author

Cairoli, R, Beghini, A, Ripamonti, C, Grillo, G, Nadali, G, Di Bona, E, Colapietro, P, Bertani, G, Ravelli, E, Nador, G, Castagnola, C, Cattaneo, C, Ottaviani, E, Pioltelli, P, Viola, A, Cuneo, A, Ferrara, F, Martinelli, G, Lazzarino, M, Rossi, G, Pizzolo, G, Morra, E, Ripamonti, CB, Bertani, GB, Cairoli, R, Beghini, A, Ripamonti, C, Grillo, G, Nadali, G, Di Bona, E, Colapietro, P, Bertani, G, Ravelli, E, Nador, G, Castagnola, C, Cattaneo, C, Ottaviani, E, Pioltelli, P, Viola, A, Cuneo, A, Ferrara, F, Martinelli, G, Lazzarino, M, Rossi, G, Pizzolo, G, Morra, E, Ripamonti, CB, and Bertani, GB

Published
2008

8. Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with INV(16)

Author

Cairoli, R, Beghini, A, Ripamonti, C, Grillo, G, Nadali, G, Di Bona, E, Colapietro, P, Nichelatti, M, Ravelli, E, Nador, G, Cuneo, A, Castagnola, C, Viola, A, Ottaviani, E, Colarossi, S, Cattaneo, C, Parma, M, Pioltelli, P, Ferrara, F, Lazzarino, M, Rossi, G, Rodeghiero, F, Pizzolo, G, Martinelli, G, Morra, E, Ripamonti, CB, Cairoli, R, Beghini, A, Ripamonti, C, Grillo, G, Nadali, G, Di Bona, E, Colapietro, P, Nichelatti, M, Ravelli, E, Nador, G, Cuneo, A, Castagnola, C, Viola, A, Ottaviani, E, Colarossi, S, Cattaneo, C, Parma, M, Pioltelli, P, Ferrara, F, Lazzarino, M, Rossi, G, Rodeghiero, F, Pizzolo, G, Martinelli, G, Morra, E, and Ripamonti, CB

Published
2007

9. Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes

Author

Nador, G, Molteni, A, Cesana, C, Nichelatti, M, Scarpati, B, Cairoli, R, Barbarano, L, Nosari, A, Morra, E, Nador, G, Molteni, A, Cesana, C, Nichelatti, M, Scarpati, B, Cairoli, R, Barbarano, L, Nosari, A, and Morra, E

Abstract

Introduction: Although blast-rich specimens immunophenotype studies in myelodysplastc syndromes (MDS) could associate bone marrow (BM) blast expression of CD7 and/or CD117 antigens with poor outcome (Ogata et al., Blood 2002), the prognostic role of markers of myeloid cell immaturity and committment in not enriched BM samples is largely unexplored. Patients and Methods: The expression of CD33, CD34 and CD117 antigens in not enriched BM samples of 50 newly diagnosed MDS was compared with both BM blast WHO category and IPSS score. Immunophenotyping was carried out by using the panel of quadruple monoclonal antibodies CD34/CD117/CD45/CD33, conjugated with the fluorochromes FITC, PE, PerCP, APC, respectively. Acquisition of information on 1x105 stained cells corresponding to the whole BM cellularity was assessed on a dual-laser FACSCalibur flow cytometer using the CellQUEST software (Becton Dickinson, San José CA USA). Multiple group comparisons were made using non parametric ANOVA for BM blasts; general linear model with Wald’s test and Kruskal-Wallis (KW) test to confirm significance was used for IPSS. Results: According to IPSS, 5 (10%) low risk, 27 (54%) intermediate risk-1, 14 (28%) intermediate risk −2 and 4 (8%) high risk pts were identified, respectively. The expression of CD33, CD34 and CD117 significantly correlated with both blast WHO category and IPSS, as shown in the Table 1. Interestingly, by analyzing the subset of 30 pts with BM blasts <5%, a correlation was found between IPSS and the expression of both CD33 (p=0.0097) and CD34 (p=0.0299); CD117 expression increased in pts with higher IPSS, without, however, reaching statistical significance. Conclusions: Both markers of myeloid cell committment (i.e., CD33 and CD34) and markers of myeloid cell immaturity (i.e., CD117) correlate with BM blast WHO category and IPSS score. Expression of CD33 and CD34 may have prognostic significance independently from blast percentage. The evaluation of CD33, CD34 and

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results